Molecular monitoring by CDKN2A/p16INK4A and RB1 gene methylation in breast cancer.

OBJECTIVE: This prospective study aimed to provide a comprehensive analysis of the methylation status of two pivotal genes, CDKN2A/p16INK4A (cyclin-dependent kinase inhibitor 2A) and RB1 (retinoblastoma transcriptional corepressor 1), in breast cancer patients. METHODS: Samples were obtained from 15 women diagnosed with breast cancer and who underwent a total mastectomy. DNA was extracted from the tumor, non-tumor tissue, and peripheral blood (circulating cell-free DNA). The methylation pattern of cell-free DNA extracted from blood collected on the day of mastectomy was compared with the methylation pattern of cell-free DNA from blood collected 1 year post-surgery. The methylation analysis was carried out by sodium bisulfite conversion and polymerase chain reaction, followed by electrophoresis. RESULTS: Methylation of CDKN2A/p16INK4A was identified in 13 tumor samples and 12 non-tumor tissue samples. Two patients exhibited CDKN2A/p16INK4A methylation in the cell-free DNA of the first blood collection, while another showed methylation only in the cell-free DNA of the subsequent blood collection. Regarding RB1, 11 tumors and 8 non-tumor tissue samples presented methylation of the gene. CONCLUSION: This study presents a novel approach for monitoring breast cancer patients through the analysis of cell-free DNA methylation. This analysis can detect changes in methylation patterns before any visible sign of cancer appears in breast tissue and could help predict the recurrence of malignant breast tumors.

hTERT gene methylation in circulating DNA, tumor, and surrounding tissue in breast cancer: a prospective study.

BACKGROUND: The human telomerase reverse transcriptase (hTERT) enzyme, encoded by the hTERT gene, synthesizes protective telomeric sequences on chromosomes and plays a fundamental role in cancer formation. Methylation of the hTERT gene has an upregulatory effect, increasing hTERT enzyme synthesis and allowing continuous tumor cell division. OBJECTIVE: In a group of patients with breast cancer, we aimed to analyze the methylation status of hTERT in the tumor, surrounding tissue, and circulating free deoxyribonucleic acid (cfDNA) of blood collected on the day of mastectomy and then approximately one year later. DESIGN AND SETTING: A prospective study was conducted at a university hospital in Rio de Janeiro, Brazil. METHODS: Samples were collected from 15 women with breast cancer on the day of mastectomy and approximately one year postoperatively. cfDNA was analyzed by sodium bisulfite conversion, followed by polymerase chain reaction, electrophoresis, and silver nitrate staining. RESULTS: Methylation of hTERT was detected in the tumors and surrounding tissues of all 15 patients. Five patients displayed hTERT methylation in the cfDNA from the blood of the first collection. Of the ten patients who returned for the second collection, three showed methylation. Two patients with methylation in the first collection did not display methylation in the second collection. One patient with no methylation in the first collection displayed methylation in the second collection, and one patient had a diminished level of methylation in the second collection. CONCLUSION: Only one-third of patients displayed methylation in their cfDNA, which may be related to the success of chemotherapy.

Molecular monitoring by CDKN2A/p16INK4A and RB1 gene methylation in breast cancer

SUMMARY OBJECTIVE: This prospective study aimed to provide a comprehensive analysis of the methylation status of two pivotal genes, CDKN2A/p16INK4A (cyclin-dependent kinase inhibitor 2A) and RB1 (retinoblastoma transcriptional corepressor 1), in breast cancer patients. METHODS: Samples were obtained from 15 women diagnosed with breast cancer and who underwent a total mastectomy. DNA was extracted from the tumor, non-tumor tissue, and peripheral blood (circulating cell-free DNA). The methylation pattern of cell-free DNA extracted from blood collected on the day of mastectomy was compared with the methylation pattern of cell-free DNA from blood collected 1 year post-surgery. The methylation analysis was carried out by sodium bisulfite conversion and polymerase chain reaction, followed by electrophoresis. RESULTS: Methylation of CDKN2A/p16INK4A was identified in 13 tumor samples and 12 non-tumor tissue samples. Two patients exhibited CDKN2A/p16INK4A methylation in the cell-free DNA of the first blood collection, while another showed methylation only in the cell-free DNA of the subsequent blood collection. Regarding RB1, 11 tumors and 8 non-tumor tissue samples presented methylation of the gene. CONCLUSION: This study presents a novel approach for monitoring breast cancer patients through the analysis of cell-free DNA methylation. This analysis can detect changes in methylation patterns before any visible sign of cancer appears in breast tissue and could help predict the recurrence of malignant breast tumors.

hTERT gene methylation in circulating DNA, tumor, and surrounding tissue in breast cancer: a prospective study

ABSTRACT BACKGROUND: The human telomerase reverse transcriptase (hTERT) enzyme, encoded by the hTERT gene, synthesizes protective telomeric sequences on chromosomes and plays a fundamental role in cancer formation. Methylation of the hTERT gene has an upregulatory effect, increasing hTERT enzyme synthesis and allowing continuous tumor cell division. OBJECTIVE: In a group of patients with breast cancer, we aimed to analyze the methylation status of hTERT in the tumor, surrounding tissue, and circulating free deoxyribonucleic acid (cfDNA) of blood collected on the day of mastectomy and then approximately one year later. DESIGN AND SETTING: A prospective study was conducted at a university hospital in Rio de Janeiro, Brazil. METHODS: Samples were collected from 15 women with breast cancer on the day of mastectomy and approximately one year postoperatively. cfDNA was analyzed by sodium bisulfite conversion, followed by polymerase chain reaction, electrophoresis, and silver nitrate staining. RESULTS: Methylation of hTERT was detected in the tumors and surrounding tissues of all 15 patients. Five patients displayed hTERT methylation in the cfDNA from the blood of the first collection. Of the ten patients who returned for the second collection, three showed methylation. Two patients with methylation in the first collection did not display methylation in the second collection. One patient with no methylation in the first collection displayed methylation in the second collection, and one patient had a diminished level of methylation in the second collection. CONCLUSION: Only one-third of patients displayed methylation in their cfDNA, which may be related to the success of chemotherapy.

Epstein-Barr virus in gastric cancer and association with 30 bp del-latent membrane protein 1 polymorphism.

OBJECTIVE: This study aimed to determine the frequencies of Epstein-Barr virus, types 1 and 2 infection, and 30 bp del-latent membrane protein 1 viral polymorphism in gastric adenocarcinomas, as well as to investigate the association between Epstein-Barr virus infection and tumor location, type, and the patient's sex. METHODS: Samples were collected from 38 patients treated at a university hospital in Rio de Janeiro, Brazil. Epstein-Barr virus detection and genotyping were performed by polymerase chain reaction, followed by polyacrylamide gel electrophoresis and staining by the silver nitrate method. RESULTS: Overall, 68.4% of patients had Epstein-Barr virus-positive tumors. Of these, 65.4% presented infection by Epstein-Barr virus type 1, 23.1% by Epstein-Barr virus type 2, and 11.5% had coinfection with types 1 and 2. The 30 bp del-latent membrane protein 1 polymorphism was found in 42.3% of Epstein-Barr virus-positive tumors, 23.1% had the wild-type virus, and 23.1% had the wild-type and the polymorphism concomitantly. In 11.5% of Epstein-Barr virus-positive tumors, it was impossible to determine whether there was polymorphism or not. Tumor location in the antrum (22 of 38) and diffuse type (27 of 38) were predominant. There was no significant difference in Epstein-Barr virus infection or the 30 bp del-latent membrane protein 1 polymorphism between men and women. CONCLUSION: Epstein-Barr virus infection was found in 68.4% of tumors investigated in this study. To the best of our knowledge, this is the first article showing the coinfection of Epstein-Barr virus types 1 and 2 in gastric carcinoma in Brazil.

Epstein-Barr virus in gastric cancer and association with 30 bp del-latent membrane protein 1 polymorphism

SUMMARY OBJECTIVE: This study aimed to determine the frequencies of Epstein-Barr virus, types 1 and 2 infection, and 30 bp del-latent membrane protein 1 viral polymorphism in gastric adenocarcinomas, as well as to investigate the association between Epstein-Barr virus infection and tumor location, type, and the patient's sex. METHODS: Samples were collected from 38 patients treated at a university hospital in Rio de Janeiro, Brazil. Epstein-Barr virus detection and genotyping were performed by polymerase chain reaction, followed by polyacrylamide gel electrophoresis and staining by the silver nitrate method. RESULTS: Overall, 68.4% of patients had Epstein-Barr virus-positive tumors. Of these, 65.4% presented infection by Epstein-Barr virus type 1, 23.1% by Epstein-Barr virus type 2, and 11.5% had coinfection with types 1 and 2. The 30 bp del-latent membrane protein 1 polymorphism was found in 42.3% of Epstein-Barr virus-positive tumors, 23.1% had the wild-type virus, and 23.1% had the wild-type and the polymorphism concomitantly. In 11.5% of Epstein-Barr virus-positive tumors, it was impossible to determine whether there was polymorphism or not. Tumor location in the antrum (22 of 38) and diffuse type (27 of 38) were predominant. There was no significant difference in Epstein-Barr virus infection or the 30 bp del-latent membrane protein 1 polymorphism between men and women. CONCLUSION: Epstein-Barr virus infection was found in 68.4% of tumors investigated in this study. To the best of our knowledge, this is the first article showing the coinfection of Epstein-Barr virus types 1 and 2 in gastric carcinoma in Brazil.

Colorectal cancer DNA methylation patterns from patients in Manaus, Brazil

BACKGROUND: DNA methylation is commonly linked with the silencing of the gene expression for many tumor suppressor genes. As such, determining DNA methylation patterns should aid, in times to come, in the diagnosis and personal treatment for various types of cancers. Here, we analyzed the methylation pattern from five colorectal cancer patients from the Amazon state in Brazil for four tumor suppressor genes, viz.: DAPK, CDH1, CDKN2A, and TIMP2 by employing a polymerase chain reaction (PCR) specific to methylation. Efforts in the study of colorectal cancer are fundamental as it is the third most of highest incidence in the world. RESULTS: Tumor biopsies were methylated in 1/5 (20 %), 2/5 (40 %), 4/5 (80 %), and 4/5 (80 %) for CDH1, CDKN2A, DAPK, and TIMP2 genes, respectively. The margin biopsies were methylated in 3/7 (43 %), 2/7 (28 %), 7/7 (100 %), and 6/7 (86 %) for CDH1, CDKN2A, DAPK, and TIMP2, respectively. CONCLUSIONS: Our findings showed DAPK and TIMP2 to be methylated in most samples from both tumor tissues and adjacent non-neoplastic margins; thus presenting distinct methylation patterns. This emphasizes the importance of better understanding of the relation of these patterns with cancer in the context of different populations.

Estudo do polimorfismo dos genes GSTM1 e GSTT1 em dna circulante de pacientes com gliomas malignos

As enzimas GSTM1 (glutationa S-transferase mi um) e GSTT1 (glutationa S-transferase teta um) apresentam importante participação na detoxicação celular de diversos carcinógenos e,sua ausência pode facilitar o surgimento de tumores malignos. Este estudo investigou a deleção dos genes que codificam estas enzimas (GSTM1 e GSTT1 respectivamente) em noventa e cinco portadores de gliomas malignos e em cem indivíduos controle sem história decâncer, comparando as frequências de deleção em ambos os grupos. Neste estudo foi avaliada a relação existente entre deleção e tempo de sobrevida dos pacientes. Também foi investigadaa associação entre a localização anatômica do tumor e a sobrevida. A genotipagem foi realizada através da reação em cadeia pela polimerase. Os resultados revelaram uma frequência de deleção de GSTM1 de 44% nos pacientes e, de 54% no grupo controle, porémesta diferença não se mostrou estatisticamente significativa (p = 0,19). Encontrou-se deleção de GSTT1 em 11,5% dos pacientes e em 36% dos indivíduos controle, sendo esta diferençasignificativa (p = 0,00009). Os pacientes com o gene GSTM1 deletado tiveram sobrevida média de vinte e três semanas e os sem deleção, trinta e uma semanas (p = 0,86). Os pacientes com deleção de GSTT1 tiveram sobrevida média de dezenove semanas, e os sem deleção,vinte e oito semanas (p = 0,0001). A localização tumoral estava disponível para quarenta e quatro pacientes, e destes, vinte e nove, apresentavam tumor lobar, com sobrevida de trinta etrês semanas, e quinze, tinham tumor profundo, com sobrevida de trinta e nove semanas (p =0,03). Os resultados deste estudo sugerem que a deleção de GSTT1 pode estar inversamente relacionada à ocorrência de gliomas malignos, uma vez que nos pacientes a frequência de deleção foi significativamente menor do que no grupo controle. Estes resultados tambémsugerem que pacientes com tumores lobares apresentam menor sobrevida do que portadores de tumores profundos...

The enzymes GSTM1 (glutathione S-transferase mu one) and GSTT1 (glutathione Stransferase theta one) have important roles in cellular detoxification of various carcinogens. Their absence may facilitate tumors emergence. This paper investigates deletion of the geneswhich encode these enzymes (GSTM1 and GSTT1 genes respectively) in 95 patients with malignant gliomas and in a group of 100 people without cancer, comparing deletion frequencies between the two groups. In this study the relationship between deletion and survival time of patients was evaluated. It was also investigated the association betweenanatomical tumor location and survival. The genotyping was carried out by polymerase chain reaction. The results showed a GSTM1 deletion frequency of 44% in patients and 54% in control group, although this difference was not statistically significant (p = 0.19). It was found GSTT1 deletion in 11.5% of patients and 36% of control subjects and this difference was statistically significant (p = 0,00009). Patients with GSTM1 deletion had median survival of 23 weeks and, without deletion, 31 weeks (p = 0.86). Patients with GSTT1 deletion had median survival of 19 weeks, and those with presence of GSTT1, 28 weeks (p = 0,0001). The tumor location was available for 44 patients, and of these, 29 had lobar tumors with median survival of 33 weeks, and 15 had deep tumors , with survival of 39 weeks (p = 0.03). Our results suggest that GSTT1 deletion may be inversely related to the occurrence of malignant gliomas, since in the patients group, the frequency of deletion was significantly lower than in the control group. The results also suggest that patients with lobar tumors have lower survival than those with deep tumors, and, that the absence of GSTM1 or GSTT1 may decrease the survival of malignant glioma patients

Efeito do álcool perílico na expressão gênica de células de adenocarcinoma de pulmão humano / Effect of perillyl alcohol on gene expression of human pulmonary adenocarcinoma cells

OBJETIVO: Estudar a ação do álcool perílico na expressão gênica de células de adenocarcinoma de pulmão humano. MÉTODOS: Incubaram-se células de adenocarcinoma de pulmão com álcool perílico em diluições que variaram entre 0,03 por cento e 0,0003 por cento por 48 horas. Observaram-se as alterações na morfologia celular e quantificou-se a viabilidade celular pelo método do MTT (3-(4,5-dimetiltiazol-2-yl)-2,5 difeniltertrazolim brometo). Analisou-se a síntese de proteínas das amostras previamente marcadas radioativamente com 35S, através de eletroforese em gel de poliacrilamida. Determinou-se a expressão das proteínas p53 e p42/44 através do método de Western Blot. RESULTADOS: Após 48 horas de incubação, observaram-se alterações na morfologia celular para a diluição de 0,03 por cento de álcool perílico, as quais foram pouco verificadas em diluições superiores a 0,003 por cento. A inibição da viabilidade celular foi de 60,17 por cento (p < 0,001), 15,62 por cento (p < 0,001) e 11,53 por cento (p < 0,05) para as diluições de 0,03 por cento, 0,003 por cento e 0,0003 por cento de álcool perílico, respectivamente. Os resultados mostram a indução de proteínas de 110 kDa, 42 kDa e 28 kDa. Não se observou variação estatisticamente significativa para a expressão da proteína p53. Em comparação com a expressão de alfa-tubulina, a diluição de 0,003 por cento de álcool perílico provocou uma diminuição marcante da fosforilação da p44 e um aumento da fosforilação da p42. CONCLUSÃO: Os resultados apresentados sugerem novos caminhos metabólicos da ação do álcool perílico em células de adenocarcinoma de pulmão humano.

OBJECTIVE: To study the effect of perillyl alcohol on the gene expression of human pulmonary adenocarcinoma cells. METHODS: Pulmonary adenocarcinoma cells were incubated with perillyl alcohol in dilutions ranging from 0.03 percent to 0.0003 percent for 48 hours. Alterations were observed in the cell morphology, and cell viability was quantified using [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assays. Protein synthesis of samples previously targeted with S35 was analyzed using electrophoresis on a polyacrylamide gel. Expression of the proteins p53 and p44/42 was determined using the Western blot method. RESULTS: After 48 hours of incubation, greater nsumbers of morphological alterations were observed in cells treated with the 0.03 percent perillyl alcohol dilution than in those treated with perillyl alcohol diluted to 0.003 percent or further. Treatment with perillyl alcohol dilutions of 0.03 percent, 0.003 percent and 0.0003 percent inhibited cellular viability by 60.17 percent (p < 0.001), 15.62 percent (p < 0.001) and 11.53 percent (p < 0.05), respectively. The results show that 28-kDa, 42-kDa and 110-kDa proteins were induced. No statistically significant effect on p53 expression was observed. In comparison with the expression of alpha-tubulin, the 0.003 percent perillyl alcohol dilution induced an increase in p42 phosphorylation and a marked decrease in p44 phosphorylation. CONCLUSION: The results suggest that there are other, previously undescribed, metabolic pathways for perillyl alcohol effects in human pulmonary adenocarcinoma cells.